Adolescents with acute lymphatic leukaemia achieve significantly better results when treated following Dutch paediatric oncology protocols than with adult protocols;Adolescenten met acute lymfatische leukemia; bij behandeling volgens Nederlandse kinderoncologische protocollen significant betere resultaten dan bij het volgen van protocollen voor volwassenen

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 8, 2005, Pages 400-406

  De Bont, J M ^a,b   Van Der Holt, B ^d   Dekker, A W ^f   Van Der Does van Den Berg, A ^g   Sonneveld, P ^e   Pieters, R ^a,b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c Stichting Kinderoncologie Nederland   (Netherlands)

^d Afd Trials en Statistiek   (Netherlands)

^e Locatie Centrum   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g SKION   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; HUMAN; MAINTENANCE THERAPY; MORTALITY; NETHERLANDS; ONCOLOGY; RECURRENCE RISK; SURVIVAL RATE; TIME SERIES ANALYSIS; TREATMENT OUTCOME; ACUTE DISEASE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; COMPARATIVE STUDY; FEMALE; MALE; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; NETHERLANDS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 14644425248     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Nachman J, Sather HN, Buckley JD, Gaynon PS, Steinherz PG, Tubergen DG, et al. Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer 1993;71:3377-85.
2. Stock W, Sather HN, Dodge CD, Bloomfield RA, Larson RA, Nachman J. Outcome of adolescents and young adults with ALL: a comparison of children's cancer group (CCG) and cancer and leukemia group B (CALGB) regimens [abstract]. Blood 2000;96:467a.
3. Boissel N, Auclerc MF, Lheritier V, Parel Y, Thomas X, Leblanc T, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003;21:774-80.
4. Veerman AJ, Hahlen K, Kamps WA, Leeuwen EF van, Vaan GA de, Solbu G, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 1996;14:911-8.
5. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, Wering ER van, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002;16:1099-11.
6. Kamps WA, Bokkerink JPM, Hahlen K, Hermans J, Riehm H, Gadner H, et al. Intensive treatment for children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results for Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood 1999;94:1226-36.
7. Dekker AW, Veer MB van 't, Sizoo W, Haak HL, Lelie J van der, Ossenkoppele G, et al. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. J Clin Oncol 1997;15:476-82.
8. Visser O, Siesling S, Dijck JAAM van, editors. Incidence of cancer in the Netherlands 1999/2000. Eleventh report of the Netherlands Cancer Registry. Utrecht: Vereniging van Integrale Kankercentra; 2003.
9. Fiere D, Schaison G, Bancillon A, Sebban C. What is the best treatment for patients between 15 y and 20 y with acute lymphoblastic leukemia (ALL)? Comparative results of two protocols, one for adults, one for children [abstract]. Blood 1990;76:270a.
10. Abromowitch M, Ochs J, Pui CH, Kalwinsky D, Rivera GK, Fairclough D, et al. High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St Jude total therapy study x. Med Pediatr Oncol 1988;16:297-303.
11. Pui CH, Simone JV, Hancock ML, Evans WE, Williams DL, Bowman WP, et al. Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude total therapy study X. Leukemia 1992;6:150-7.
12. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. J Clin Oncol 1993;11:520-6.
13. Richards S, Gray R, Peto R, Gaynon P, Masera G. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12000 randomised children. Lancet 1996;347:1783-8.
14. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol 1993;11:527-37.
15. Chesselis JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Lancet 1995;345:143-8.
16. Lange B, Sather H, Weetman R. Double delayed intensification improves outcome in moderate risk pediatric acute lymphoblastic leukemia: a Childrens Cancer Group study, CCG-1891 [abstract]. Blood 1997;90:2489.
17. Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000;18:1508-16.
18. Dibenedetto SP, Guardabasso V, Ragusa R, di Cataldo A, Miraglia V, D'Amico S, et al. 6-Mercaptopurine cumulative dose: a critical factor of maintenance therapy in average risk childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1994;11:251-8.
19. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999;93:2817-23.
20. Arico M, Valsecchi MG, Camitta B. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006.
21. Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol 2000;27:540-59.
22. Weisdorf DJ, Billett AL, Hannan P, Ritz J, Sallan SE, Steinbuch M, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 1997;90:2962-8.
23. Vey N, Blaise D, Stoppa AM, Bouabdallah R, Lafage M, Sainty D, et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 1994;14:383-8.
24. Bassan R, Lerede T, Barbui T. Institutional performance and dose intensity as prognostic factors in adult ALL. Leukemia 1995;9:933-4.
25. Chiu EK, Chan LC, Liang R. Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect. Leukemia 1994;8:1469-73.
26. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a pediatric oncology group study. Leukemia 1999;13:335-42.
27. Silverman LB, Gelber RD, Datton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-8.
28. Jones B, Freeman AI, Shuster JJ, Jacquillat C, Weil M, Pochedly C, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991;19:269-75.
29. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003;101:3809-17.
30. Styczynski J, Pieters R, Huismans DR, Schuurhuis GJ, Wysocki M, Veerman AJ. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. Br J Haematol 2000;110:813-8.